Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

1. Insulin (Kixelle) - diabetes

Insulin (Kixelle) - diabetes Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/704954/2020 EMEA/H/C/004965 Kixelle (insulin aspart) An overview of Kixelle and why (...) it is authorised in the EU What is Kixelle and what is it used for? Kixelle is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Kixelle is a ‘biosimilar medicine’. This means that Kixelle is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Kixelle is NovoRapid. For more information on biosimilar medicines, see here. Kixelle contains the active substance insulin

2021 European Medicines Agency - EPARs

2. Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin

Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr;44(4):1059-1061. doi: 10.2337/dc20-1558. Epub 2021 Feb 3. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin , , , , , , , , Affiliations Expand Affiliations 1 Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China. 2

2021 EvidenceUpdates

3. Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2) Full Text available with Trip Pro

Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2 , , , , , , , Affiliations Expand Affiliations 1 Diabetes-Zentrum für Kinder und Judendliche, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany. 2 Department of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California. 3 Taking Control of Your Diabetes, Solana

2021 EvidenceUpdates

4. Insulin aspart (Trurapi) - for the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia

Insulin aspart (Trurapi) - for the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2021 Health Canada - Drug and Health Product Register

5. Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis

Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) . 2021 Feb;23(2):540-548. doi: 10.1111/dom.14247. Epub 2020 Dec 2. Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, China. 2 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Medical College, Xi'an

2021 EvidenceUpdates

6. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial

Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Int J Clin Pract Actions . 2020 Oct 25;e13734. doi: 10.1111/ijcp.13734. Online ahead of print. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan. 2

2020 EvidenceUpdates

7. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) navigation Diabetes Care Actions . 2020 Dec;43(12):3024-3033. doi: 10.2337/dc20-1447. Epub 2020 Oct 14. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial , , , , , , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators Australian JDRF Closed-Loop Research Group : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1

2020 EvidenceUpdates

8. Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin glargin/Lixisenatid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 July 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-38 Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-38 Version 1.0 Insulin glargine/lixisenatide (type 2 diabetes mellitus) 13 July 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Insulin glargine/lixisenatide (type 2

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes Full Text available with Trip Pro

Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard (...) Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14191. Online ahead of print. Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes , , , , , Affiliations Expand Affiliations 1 Eli Lilly and Company, Indianapolis, Indiana, USA. 2 Insulet Corporation, Billerica, Massachusetts, USA. PMID: 32893428 DOI: Item in Clipboard Patient-reported

2020 EvidenceUpdates

10. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies Full Text available with Trip Pro

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Actions . 2020 Nov;43(11):2713-2720. doi: 10.2337/dc20-0924. Epub 2020 Sep 14. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies , , , , , , , , , , Affiliations Expand Affiliations 1 Keck School of Medicine of the University of Southern California, Los Angeles, CA annepete@med.usc.edu. 2 University of Texas Southwestern Medical Center at Dallas, Dallas, TX. 3 Kinder Krakenhaus auf der Bult

2020 EvidenceUpdates

11. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Full Text available with Trip Pro

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 29. doi: 10.1111/dom.14202. Online ahead of print. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Centre of Research Excellence in Translating Nutritional Science to Good Health, University

2020 EvidenceUpdates

12. Insulins (all types): risk of cutaneous amyloidosis at injection site

Insulins (all types): risk of cutaneous amyloidosis at injection site Insulins (all types): risk of cutaneous amyloidosis at injection site - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions in England from 5 November Take action (...) now for new rules in 2021 Insulins (all types): risk of cutaneous amyloidosis at injection site Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region. Published 23 September 2020 From: Therapeutic area: Contents Advice for healthcare professionals: injection of insulin (all types) can lead to deposits of amyloid protein under the skin (cutaneous amyloidosis

2020 MHRA Drug Safety Update

13. Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study Full Text available with Trip Pro

Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study - PubMed This site needs JavaScript to work (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Jul 30. doi: 10.1111/dom.14153. Online ahead of print. Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study , , , , , Affiliations Expand Affiliations 1 Division of Diabetes, University of Texas Health Science

2020 EvidenceUpdates

14. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes

t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes Medtech innovation briefing Published: 22 September 2020 www.nice.org.uk/guidance/mib227 pathways Summary Summary • The technology technology described in this briefing is the t:slim X2 insulin pump. It is used for managing blood glucose levels in type 1 diabetes. • The innovative aspects innovative aspects are using advanced algorithms (...) with a continuous glucose monitor to predict low glucose and suspend insulin delivery. The technology software, Control-IQ, can also adjust basal insulin and give correction doses. • The intended place in therapy place in therapy would be as an alternative to other sensor-augmented insulin pumps for people with type 1 diabetes. • The main points from the evidence main points from the evidence summarised in this briefing are from 6 studies (including 4 randomised controlled trials, 1 randomised crossover study

2020 National Institute for Health and Clinical Excellence - Advice

15. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. (Abstract)

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes.We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety (...) of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor. The primary end point was the change in glycated hemoglobin level from baseline to week 26. Safety end points, including episodes of hypoglycemia and insulin-related adverse events

2020 NEJM

18. Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review Full Text available with Trip Pro

Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review Danylo Rafhael Costa-Silva, Francisco Adelton Alves-Ribeiro, Maria da Conceição Barros-Oliveira, Larysse Cardoso Campos-Verdes, Renato de Oliveira Pereira, Cleciton Braga Tavares, Mariella de Almeida Melo, Arquimedes Cavalcante Cardoso, Eid

2020 Research Square

19. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Full Text available with Trip Pro

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial - PubMed This site needs JavaScript to work properly (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 21;dc192316. doi: 10.2337/dc19-2316. Online ahead of print. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial , , , , , , , , Affiliations Expand Affiliations 1 Dallas Diabetes Research Center at Medical City

2020 EvidenceUpdates

20. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2

Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Metab Actions . 2020 Jul 3. doi: 10.1111/dom.14127. Online ahead of print. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 , , , , , , , Affiliations Expand Affiliations 1 Endocrine and Metabolic Consultants, Rockville, Maryland, USA. 2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3 Diabetes Centers of America-Dallas

2020 EvidenceUpdates